Benoît Tessoulin

机构：Centre National de la Recherche Scientifique, Inserm, Centre Hospitalier Universitaire de Nantes, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, CHU Dijon Bourgogne, Centre d'Investigation Clinique de Nantes, Nantes Université · ORCID：0000-0001-7600-3329

发表论文 230 篇 · 总被引 3430 次 · h-index 31

代表论文

• Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 19)
• Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18–65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network (2026 · The Lancet · 被引 8)
• Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study (2025 · Blood · 被引 6)
• Prognostic impact and safety of early adjunctive corticosteroid therapy in HIV-negative severe pneumocystis pneumonia: a propensity-matched multicentre study (2025 · Thorax · 被引 3)
• Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies (2025 · Clinical Lymphoma Myeloma & Leukemia · 被引 3)
• Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials (2025 · Blood Cancer Journal · 被引 2)